Skip To Main Content
Ryan Wiegand on Muck Rack

Ryan Wiegand

Atlanta
As seen in: Center for Disease Control and Prevention, Emerging Infectious Diseases Journal, Nature, Wiley Online Library, JAMA (The Journal of the American Medical Association), JAMA Network, JAMA: Journal of the American Medical Association, Medscape, The Lancet, Dialnet - Universidad de La Rioja and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ryan

Contact Ryan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design

|
By Ryan Wiegand, Sean Chickery, Duck-Hye Yang, Sarah Ball Verified, Malini DeSilva, Kristin Dascomb, Stephanie A. Irving, Karthik Natarajan, Nicola P. Klein, Shaun Grannis, Toan C Ong, Elizabeth Rowley, Adam Yates, Yan Zhuang Verified, Charlene E. McEvoy, Omobosola Akinsete, Allison L. Naleway, Padma Koppolu, Ousseny Zerbo, John Hansen, Karen B. Jacobson, Lawrence Block, Thomas Duszynski, Colin Rogerson, Michelle Barron, Catia Chávez, Josephine Mak, Allison Avrich Ciesla, Monica Godfrey, Morgan Najdowski, Ruth Link-Gelles, Jennifer DeCuir, Amanda Payne, Inih J. Essien, Amber Kautz
| JAMA Network Verified
Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design Supplement 1. eTable 1. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) used to define COVID-19-like illness eTable 2. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) used to define underlying medical condition and immunocompromise status Supplement 2. Table 1.
Open in Who Shared Issue with article?

COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years — United States, June 1, 2023–September 30, 2025

|
By Julia Raykin, Ilia Rochin, Ryan Wiegand
| A Cup of Health with CDC
Methods This retrospective cohort study examined deidentified electronic health records from Truveta, which collects data from health care organizations nationwide, including approximately 120 million patients receiving care at approximately 20,000 clinics and 900 hospitals in the United States. Data are transformed using the Truveta Data Model and standardized through the Truveta Language Model. Data from June 1, 2023, through September 30, 2025, were extracted in January 2026 for this analysis.
Open in Who Shared Issue with article?

Using Multiple Methods to Estimate Respiratory Syncytial Virus (RSV)‐associated Hospitalization Rates in Children Aged < 5 Years-Hamilton County, Ohio, 2009-2017 - Harker - 2025 - Influenza and Other Respiratory Viruses - Wiley Online Library

|
By Elizabeth Harker, Ryan Wiegand, Erica Rose, Marilyn Rice
| Wiley Online Library Verified
1 Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in children less than 5 years of age worldwide. Globally, RSV is estimated to cause more than 3 million hospitalizations and between 66,000 and 199,000 deaths, with 20% of hospitalized children with acute respiratory infections (ARIs) infected with RSV [1-4].
Open in Who Shared Issue with article?
See all 16 licensed articles (27 Total)